摘要
用重组人γ-干扰素(rIFNγ)处理肝癌病人外周血单个核细胞(PBMC),观察细胞膜表面IgG Fc段受体(FcγR)的表达情况。ABC-ELISA方法检测FcγR。结果显示,肝癌病人内源性IFNγ水平及FcγR基础水平均低下。rIFNγ处理后,肝癌患者PBMC FcγR表达明显增强,并与rIFNγ的剂量呈正相关。但对rIFNγ的增强效应显著低于正常对照组。推测,在肝癌病人,IFNγ的产生及FcγR的表达均有缺陷,外源性rIFNγ可通过增强FcγR表达发挥其免疫调节作用,是抗肿瘤机制之一。
PBMC from 9 patients were treated with rIFNγ. FcrR was determined with ABC-ELISA before and after treatment with rIFNy or anti-IFNγ monoclonal antibody (mAb). The results showed rIFNγ potently enhanced the expression of FcγR, although the effect was much less than in normal control. The effect of enhancement by rIFNγ was dose-dependent. With the dose of 10U/ml, rIFNy exerts a moderate but significant enhancement, and the maximal effect is observed when 1000U/ml was used. In normal control, after PBMC were cultured for 24 h in RPMI 1640 without rIFNγ, mean value of P-N (0.833 + 0.483) was significantly increased, which could be abolished if 100U/ml rIFNγ -mAb were present in the medium. IFNγ activity (13.6 + 7.58 antiviral unit/ml) was detected from all the PBMC medium, suggesting that endogenous IFNγ may influence the expression of FcγR. However, no increase was observed in cultured PBMC from PHC patients, and IFNγ was also not detectable in medium except in one case (8U/ml). These results suggested: (1) exogenous IFNγ regulates expression of FcrR in PHC patients, which would be involved in anti-tumor mechanisms, (2) the production of IFNy in PHC patients is defective, resulting in, at least partially, reduced expression FcrR.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
1991年第6期431-434,共4页
Medical Journal of Chinese People's Liberation Army
